Literature DB >> 29864611

The profile of cognitive impairments in chronic ketamine users.

Xiaoyin Ke1, Yi Ding2, Ke Xu3, Hongbo He2, Daping Wang2, Xuefeng Deng4, Xifan Zhang4, Yanling Zhou2, Chao Zhou2, Yuping Liu2, Yuping Ning5, Ni Fan6.   

Abstract

The aim of this study was to examine the cognitive function in chronic ketamine users. Factors correlated to cognition impairments were analyzed. Sixty-three chronic ketamine users and 65 healthy subjects were recruited. Cognitive function was assessed by using immediate/delayed visual reproduction (IVR/DVR) tasks, immediate/delayed logical memory (ILM/DLM) tasks, Stroop test, Wisconsin card sorting test (WCST), and continuous performance test (CPT). Psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Ketamine users performed worse than controls on the IVR, ILM, DLM, Stroop and auditory CPT tests. IVR and DVR, color-naming and color-interference-reading scores were positively correlated with education level. In ketamine users ILM scores were negatively correlated with the negative subscale of PANSS. DLM score was positively correlated with average dose of ketamine use. Word-reading score was positively correlated with education level, and negatively correlated with duration of ketamine use. False hits in auditory CPT was positively correlated with duration of ketamine use. Number of trials to complete the first category and perseverative errors on WCST were positively correlated with the duration between the test and last ketamine use. Chronic ketamine users had cognitive impairments across multiple domains.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cognitive function; Depression; Ketamine; Psychotic symptoms

Mesh:

Substances:

Year:  2018        PMID: 29864611     DOI: 10.1016/j.psychres.2018.05.050

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

2.  Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine.

Authors:  Ying Wei; Li Xiao; Weihao Fan; Jing Zou; Hong Yang; Bo Liu; Yi Ye; Di Wen; Linchuan Liao
Journal:  J Mol Neurosci       Date:  2022-07-08       Impact factor: 2.866

3.  A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain.

Authors:  Vinita Singh; Theresa W Gillespie; Olabisi Lane; Boris Spektor; Ali John Zarrabi; Katherine Egan; Kimberly Curseen; Maya Tsvetkova; Jan H Beumer; Roman Sniecinski; Jack W Shteamer; Jeffery Switchenko; R Donald Harvey
Journal:  Pharmacotherapy       Date:  2022-02-21       Impact factor: 6.251

Review 4.  Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies.

Authors:  Brandon Dickey; Leelavathi N Madhu; Ashok K Shetty
Journal:  Pharmacol Ther       Date:  2020-10-24       Impact factor: 12.310

5.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

6.  Cortical Thickness Changes in Chronic Ketamine Users.

Authors:  Jun Zhong; Huawang Wu; Fengchun Wu; Hongbo He; Zhaohua Zhang; Jiaxin Huang; Penghui Cao; Ni Fan
Journal:  Front Psychiatry       Date:  2021-03-25       Impact factor: 4.157

7.  Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.

Authors:  Danika Dai; Courtney Miller; Violeta Valdivia; Brian Boyle; Paula Bolton; Shuang Li; Steve Seiner; Robert Meisner
Journal:  BMC Psychiatry       Date:  2022-02-22       Impact factor: 3.630

8.  Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling.

Authors:  Yayan Luo; Yang Yu; Minling Zhang; Hongbo He; Ni Fan
Journal:  Mol Psychiatry       Date:  2020-06-02       Impact factor: 15.992

9.  Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study.

Authors:  Wei Zheng; Yan-Ling Zhou; Cheng-Yu Wang; Xiao-Feng Lan; Bin Zhang; Ming-Zhe Yang; Sha Nie; Yu-Ping Ning
Journal:  PeerJ       Date:  2020-11-03       Impact factor: 2.984

Review 10.  Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?

Authors:  Meiying Cui; Wanlin Dai; Jing Kong; Hongzhi Chen
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.